Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.

CONCLUSIONS: We report the first evidence of potential anti-parkinsonian efficacy of the oral selective D1/D5 partial agonist PF-06412562 without the significant acute changes in cardiovascular parameters reported with previous D1 agonists. PMID: 30453303 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30453303?dopt=Abstract

Source: Neuro-Degenerative Diseases - November 19, 2018 Category: Neurology Authors: Papapetropoulos S, Liu W, Duvvuri S, Thayer K, Gray DL Tags: Neurodegener Dis Source Type: research